根据trem-cel研究数据，Vor Bio股价盘后上涨

Vor Bio (NASDAQ:VOR) stock rallied 64% in post-market trading Thursday after the company reported positive data for its gene-edited stem cell therapy trem-cel in the treatment of acute myeloid leukemia, or AML.

The Phase 1/2 study, called VBP101, is evaluating trem-cel in combination with Pfizer’s (PFE) Mylotarg in the treatment of patients with relapsed/refractory AML.

Vor (VOR) said in a statement that the study data “demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit.”

The company intends to approach the FDA to discuss a pivotal trial design for the trem-cel plus Mylotarg combination around the end of the year, it added.

Vor (VOR) also announced it was progressing with studies that would enable Phase 1 testing for another therapy candidate, an antibody drug conjugate called VADC45.